Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and bexarotene, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Bexarotene may also cause cutaneous T-cell lymphoma cells to look more
like normal cells, and to grow and spread more slowly. Giving liposomal doxorubicin followed
by bexarotene may be an effective treatment for cutaneous T-cell lymphoma.
PURPOSE: This phase II trial is studying how well giving liposomal doxorubicin followed by
bexarotene works in treating patients with cutaneous T-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Hackensack Meridian Health Hackensack University Medical Center M.D. Anderson Cancer Center National Cancer Institute (NCI) New York University School of Medicine NYU Langone Health Roswell Park Cancer Institute Tibotec Pharmaceutical Limited